Delivery Might Be Key to Gene Therapy’s Orphan Status, CBER Official Says

Drug Industry Daily
A A
The FDA will consider granting orphan status for different gene therapies—even ones in the same class as a previously designated orphan treatment—based on how the therapy is delivered, a high-ranking CBER official said Friday at the Food and Drug Law Institute’s annual meeting in Washington, D.C.

To View This Article:

Login

Subscribe To Drug Industry Daily